A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy
Information source: National Taiwan University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pneumocystis Jirovecii Pneumonia
Phase: N/A
Status: Recruiting
Sponsored by: National Taiwan University Hospital Overall contact: Jin-Han Yang, Bachelor, Phone: 0975-103-277, Email: r01451004@ntu.edu.tw
Summary
In this study, we aim to investigate the incidence of the adverse reactions, the
effectiveness and the gene polymorphism associated with the plasma level of
sulfamethoxazole-trimethoprim and their metabolites (including N4-acetyl-sulfamethoxazole,
sulfamethoxazole hydroxylamine and sulfamethoxazole-nitroso). And we also aim to investigate
the factors associated with the sulfamethoxazole-trimethoprim induced acute psychosis.
Clinical Details
Official title: A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: High performance liquid chromatography for drug plasma concentration
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- males and females aged 20 years or older
- using oral or intravenous form of sulfamethoxazole-trimethoprim
Exclusion Criteria:
- patients who are under 20 years of age
Locations and Contacts
Jin-Han Yang, Bachelor, Phone: 0975-103-277, Email: r01451004@ntu.edu.tw
National Taiwan University Hospital, Taipei, TW 106, Taiwan; Active, not recruiting
National Taiwan University Hospital, Taipei, TW 106, Taiwan; Recruiting Jin-Han Yang, Email: r01451004@ntu.edu.tw Shu-Wen Lin, Principal Investigator
Additional Information
Starting date: January 2014
Last updated: July 31, 2014
|